Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
42
OCS Quote, Financials, Valuation and Earnings
Last price:
$20.50
Seasonality move
:
2.04%
Day range:
$20.08 - $21.11
52-week range:
$14.00 - $23.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
7.22x
Volume:
59.1K
Avg. volume:
114.3K
1-year change:
20.09%
Market cap:
$1.2B
Revenue:
--
EPS (TTM):
-$2.52
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
OCS
Oculis Holding AG
|
$170.5K | -$0.54 | -- | -36.9% | $44.72 |
|
ACIU
AC Immune SA
|
$509K | -$0.22 | 18.61% | -6.92% | $9.01 |
|
ADXN
Addex Therapeutics Ltd.
|
$242.8K | -- | 2.35% | -- | $30.00 |
|
CRSP
CRISPR Therapeutics AG
|
$2.6M | -$1.09 | -89.16% | -180.62% | $81.33 |
|
ONC
BeOne Medicines Ltd.
|
$1.4B | $0.51 | 29.38% | -70.04% | $400.06 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
OCS
Oculis Holding AG
|
$20.50 | $44.72 | $1.2B | -- | $0.00 | 0% | -- |
|
ACIU
AC Immune SA
|
$3.13 | $9.01 | $314.9M | -- | $0.00 | 0% | 61.04x |
|
ADXN
Addex Therapeutics Ltd.
|
$7.99 | $30.00 | $9.8M | 0.77x | $0.00 | 0% | 36.54x |
|
CRSP
CRISPR Therapeutics AG
|
$55.08 | $81.33 | $5.2B | -- | $0.00 | 0% | 125.63x |
|
ONC
BeOne Medicines Ltd.
|
$312.39 | $400.06 | $34.6B | 601.10x | $0.00 | 0% | 6.98x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
OCS
Oculis Holding AG
|
1.85% | 1.479 | 0.34% | 4.30x |
|
ACIU
AC Immune SA
|
6.95% | 3.999 | 2.01% | 1.10x |
|
ADXN
Addex Therapeutics Ltd.
|
0.61% | 2.172 | 0.5% | 1.91x |
|
CRSP
CRISPR Therapeutics AG
|
9.92% | 3.188 | 3.47% | 16.13x |
|
ONC
BeOne Medicines Ltd.
|
31.57% | 0.334 | 5.05% | 2.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
OCS
Oculis Holding AG
|
-$188.7K | -$25.7M | -83.14% | -84.11% | -- | -$18M |
|
ACIU
AC Immune SA
|
-- | -$19.6M | -72.31% | -75.88% | -1671.93% | -$24.4M |
|
ADXN
Addex Therapeutics Ltd.
|
-- | -$869.9K | -73.49% | -73.84% | -1403.07% | -$687.4K |
|
CRSP
CRISPR Therapeutics AG
|
-$60.6M | -$132.1M | -23.42% | -26.17% | -14854.78% | -$84.7M |
|
ONC
BeOne Medicines Ltd.
|
$1.2B | $163.3M | 1.43% | 1.92% | 11.55% | $355.1M |
Oculis Holding AG vs. Competitors
-
Which has Higher Returns OCS or ACIU?
AC Immune SA has a net margin of -- compared to Oculis Holding AG's net margin of -1688.87%. Oculis Holding AG's return on equity of -84.11% beat AC Immune SA's return on equity of -75.88%.
Company Gross Margin Earnings Per Share Invested Capital OCSOculis Holding AG-- -$0.40 $167.2M ACIUAC Immune SA-- -$0.20 $84.3M -
What do Analysts Say About OCS or ACIU?
Oculis Holding AG has a consensus price target of $44.72, signalling upside risk potential of 118.17%. On the other hand AC Immune SA has an analysts' consensus of $9.01 which suggests that it could grow by 188.23%. Given that AC Immune SA has higher upside potential than Oculis Holding AG, analysts believe AC Immune SA is more attractive than Oculis Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings OCSOculis Holding AG7 0 0 ACIUAC Immune SA4 0 0 -
Is OCS or ACIU More Risky?
Oculis Holding AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.243%.
-
Which is a Better Dividend Stock OCS or ACIU?
Oculis Holding AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oculis Holding AG pays -- of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OCS or ACIU?
Oculis Holding AG quarterly revenues are --, which are smaller than AC Immune SA quarterly revenues of $1.2M. Oculis Holding AG's net income of -$21.1M is lower than AC Immune SA's net income of -$19.8M. Notably, Oculis Holding AG's price-to-earnings ratio is -- while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oculis Holding AG is -- versus 61.04x for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OCSOculis Holding AG-- -- -- -$21.1M ACIUAC Immune SA61.04x -- $1.2M -$19.8M
-
Which has Higher Returns OCS or ADXN?
Addex Therapeutics Ltd. has a net margin of -- compared to Oculis Holding AG's net margin of -3178.71%. Oculis Holding AG's return on equity of -84.11% beat Addex Therapeutics Ltd.'s return on equity of -73.84%.
Company Gross Margin Earnings Per Share Invested Capital OCSOculis Holding AG-- -$0.40 $167.2M ADXNAddex Therapeutics Ltd.-- -$2.10 $7.5M -
What do Analysts Say About OCS or ADXN?
Oculis Holding AG has a consensus price target of $44.72, signalling upside risk potential of 118.17%. On the other hand Addex Therapeutics Ltd. has an analysts' consensus of $30.00 which suggests that it could grow by 275.47%. Given that Addex Therapeutics Ltd. has higher upside potential than Oculis Holding AG, analysts believe Addex Therapeutics Ltd. is more attractive than Oculis Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings OCSOculis Holding AG7 0 0 ADXNAddex Therapeutics Ltd.0 0 0 -
Is OCS or ADXN More Risky?
Oculis Holding AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Addex Therapeutics Ltd. has a beta of 1.573, suggesting its more volatile than the S&P 500 by 57.32%.
-
Which is a Better Dividend Stock OCS or ADXN?
Oculis Holding AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addex Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oculis Holding AG pays -- of its earnings as a dividend. Addex Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OCS or ADXN?
Oculis Holding AG quarterly revenues are --, which are smaller than Addex Therapeutics Ltd. quarterly revenues of $62K. Oculis Holding AG's net income of -$21.1M is lower than Addex Therapeutics Ltd.'s net income of -$2M. Notably, Oculis Holding AG's price-to-earnings ratio is -- while Addex Therapeutics Ltd.'s PE ratio is 0.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oculis Holding AG is -- versus 36.54x for Addex Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OCSOculis Holding AG-- -- -- -$21.1M ADXNAddex Therapeutics Ltd.36.54x 0.77x $62K -$2M
-
Which has Higher Returns OCS or CRSP?
CRISPR Therapeutics AG has a net margin of -- compared to Oculis Holding AG's net margin of -11973.12%. Oculis Holding AG's return on equity of -84.11% beat CRISPR Therapeutics AG's return on equity of -26.17%.
Company Gross Margin Earnings Per Share Invested Capital OCSOculis Holding AG-- -$0.40 $167.2M CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B -
What do Analysts Say About OCS or CRSP?
Oculis Holding AG has a consensus price target of $44.72, signalling upside risk potential of 118.17%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.33 which suggests that it could grow by 47.66%. Given that Oculis Holding AG has higher upside potential than CRISPR Therapeutics AG, analysts believe Oculis Holding AG is more attractive than CRISPR Therapeutics AG.
Company Buy Ratings Hold Ratings Sell Ratings OCSOculis Holding AG7 0 0 CRSPCRISPR Therapeutics AG12 10 1 -
Is OCS or CRSP More Risky?
Oculis Holding AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.738, suggesting its more volatile than the S&P 500 by 73.75%.
-
Which is a Better Dividend Stock OCS or CRSP?
Oculis Holding AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oculis Holding AG pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OCS or CRSP?
Oculis Holding AG quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of $889K. Oculis Holding AG's net income of -$21.1M is higher than CRISPR Therapeutics AG's net income of -$106.4M. Notably, Oculis Holding AG's price-to-earnings ratio is -- while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oculis Holding AG is -- versus 125.63x for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OCSOculis Holding AG-- -- -- -$21.1M CRSPCRISPR Therapeutics AG125.63x -- $889K -$106.4M
-
Which has Higher Returns OCS or ONC?
BeOne Medicines Ltd. has a net margin of -- compared to Oculis Holding AG's net margin of 8.84%. Oculis Holding AG's return on equity of -84.11% beat BeOne Medicines Ltd.'s return on equity of 1.92%.
Company Gross Margin Earnings Per Share Invested Capital OCSOculis Holding AG-- -$0.40 $167.2M ONCBeOne Medicines Ltd.83.86% $1.09 $6B -
What do Analysts Say About OCS or ONC?
Oculis Holding AG has a consensus price target of $44.72, signalling upside risk potential of 118.17%. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $400.06 which suggests that it could grow by 28.06%. Given that Oculis Holding AG has higher upside potential than BeOne Medicines Ltd., analysts believe Oculis Holding AG is more attractive than BeOne Medicines Ltd..
Company Buy Ratings Hold Ratings Sell Ratings OCSOculis Holding AG7 0 0 ONCBeOne Medicines Ltd.18 1 1 -
Is OCS or ONC More Risky?
Oculis Holding AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.452, suggesting its less volatile than the S&P 500 by 54.771%.
-
Which is a Better Dividend Stock OCS or ONC?
Oculis Holding AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oculis Holding AG pays -- of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OCS or ONC?
Oculis Holding AG quarterly revenues are --, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.4B. Oculis Holding AG's net income of -$21.1M is lower than BeOne Medicines Ltd.'s net income of $125M. Notably, Oculis Holding AG's price-to-earnings ratio is -- while BeOne Medicines Ltd.'s PE ratio is 601.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oculis Holding AG is -- versus 6.98x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OCSOculis Holding AG-- -- -- -$21.1M ONCBeOne Medicines Ltd.6.98x 601.10x $1.4B $125M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
